Abstract:BackgroundEach year, influenza is responsible for hundreds of thousand cases of illness and deaths worldwide. Due to the virus’ fast mutation rate, the World Health Organization (WHO) is constantly on alert to rapidly respond to emerging pandemic strains. Although anti-viral therapies exist, the most proficient way to stop the spread of disease is through vaccination. The majority of influenza vaccines on the market are produced in embryonic hen’s eggs and are composed of purified viral antigens from inactivated whole virus. This manufacturing system, however, is limited in its production capacity. Cell culture produced vaccines have been proposed for their potential to overcome the problems associated with egg-based production. Virus-like particles (VLPs) of influenza virus are promising candidate vaccines under consideration by both academic and industry researchers.MethodsIn this study, VLPs were produced in HEK293 suspension cells using the Bacmam transduction system and Sf9 cells using the baculovirus infection system. The proposed systems were assessed for their ability to produce influenza VLPs composed of Hemagglutinin (HA), Neuraminidase (NA) and Matrix Protein (M1) and compared through the lens of bioprocessing by highlighting baseline production yields and bioactivity. VLPs from both systems were characterized using available influenza quantification techniques, such as single radial immunodiffusion assay (SRID), HA assay, western blot and negative staining transmission electron microscopy (NSTEM) to quantify total particles.ResultsFor the HEK293 production system, VLPs were found to be associated with the cell pellet in addition to those released in the supernatant. Sf9 cells produced 35 times more VLPs than HEK293 cells. Sf9-VLPs had higher total HA activity and were generally more homogeneous in morphology and size. However, Sf9 VLP samples contained 20 times more baculovirus than VLPs, whereas 293 VLPs were produced along with vesicles.ConclusionsThis study highlights key production hurdles that must be overcome in both expression platforms, namely the presence of contaminants and the ensuing quantification challenges, and brings up the question of what truly constitutes an influenza VLP candidate vaccine.

The baculovirus expression vector system: a modern technology for the future of influenza vaccine manufacturing

Innovations in cell culture-based influenza vaccine manufacturing - from static cultures to high cell density cultivations

From single‐cell cloning to high‐yield influenza virus production – implementing advanced technologies in vaccine process development

Cell culture-based influenza vaccines: A necessary and indispensable investment for the future

Influenza Vaccine: An Engineering Vision from Virological Importance to Production

How far have we reached in development of effective influenza vaccine?

High-Yield Expression and Purification of Recombinant Influenza Virus Proteins from Stably-Transfected Mammalian Cell Lines

Application of bioreactor technology for cell culture-based viral vaccine production: Present status and future prospects

Recent Advances, Approaches and Challenges in the Development of Universal Influenza Vaccines

Progress on adenovirus-vectored universal influenza vaccines

Critical assessment of influenza VLP production in Sf9 and HEK293 expression systems

Recent Progress in Recombinant Influenza Vaccine Development Toward Heterosubtypic Immune Response

Influenza Vaccine Effectiveness and Progress Towards a Universal Influenza Vaccine

Advances in Development and Application of Influenza Vaccines

Advances in Post-Pandemic Viral Antigen Production for Vaccines

Advancing influenza vaccines: A review of next-generation candidates and their potential for global health impact

Influenza B Virus Vaccine Innovation through Computational Design

A novel application of baculovirus in mammalian gene therapy]

Development of Baculovirus as Vaccine Vectors

Emerging Frontiers in Vaccine Development: A Review of Changing Paradigm

Production of Recombinant Viral Antigens Using the Baculovirus-Insect Cell Expression System